Short answer
Corcept Therapeutics Inc (CORT) filed its Q3 2016 10-Q quarterly report on Nov 2, 2016 for the quarter ended Sep 30, 2016.
Corcept Therapeutics Inc Q3 2016 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $21.7M, up from $13.3M YoY, driven by higher Korlym volume and price increases
- GAAP net income $2.585M vs $601K loss YoY, with R&D expense $7.1M vs $3.6M
- Cost of sales margin 3.1% vs 1.9% YoY, reflecting a one-time manufacturer expenditure
- R&D focus: selective cortisol modulators $3.9M vs $1.1M YoY, the largest project category
- Cash $47.9M vs $40.4M at December 2015, operating cash flow $13.8M, Biopharma payments $10.3M
- Outlook: cash-flow breakeven expected, CORT125134 trials advancing, obligation repayment expected in 2017
Risk Factors
- No material changes from the most recent 10-K stated; risks remain substantially carried forward
- Regulatory compliance: February 1, 2016 CMS rule may alter Korlym reported prices, rebates and chargebacks
- Commercial risk: Korlym faces competition from Novartis’s Signifor and osilodrostat development programs
- Supply risk: PCAS supplies all Korlym API and Alcami produces all Korlym tablets
- Financial risk: Biopharma receives 20% of covered-product sales until payments reach $45.0 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Corcept Therapeutics Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 1, 2019
- Q1 2019 10-QFiled May 9, 2019
- Q3 2018 10-QFiled Nov 2, 2018
- Q2 2018 10-QFiled Aug 9, 2018
- Q1 2018 10-QFiled May 9, 2018
- Q3 2017 10-QFiled Nov 3, 2017
- Q2 2017 10-QFiled Aug 2, 2017
- Q1 2017 10-QFiled May 2, 2017
- Q2 2016 10-QFiled Aug 3, 2016
- Q1 2016 10-QFiled May 4, 2016
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.